- Report
- January 2022
- 60 Pages
Global
From €3506EUR$3,950USD£3,018GBP
- Report
- January 2023
- 153 Pages
Europe
From €3062EUR$3,450USD£2,636GBP
- Report
- October 2022
- 209 Pages
Global
From €3950EUR$4,450USD£3,400GBP
- Report
- August 2022
- 120 Pages
Global
From €4216EUR$4,750USD£3,629GBP
- Report
- January 2023
- 124 Pages
From €3062EUR$3,450USD£2,636GBP
- Report
- January 2023
- 134 Pages
Africa, Middle East
From €3062EUR$3,450USD£2,636GBP
- Report
- January 2023
- 160 Pages
Asia Pacific
From €3062EUR$3,450USD£2,636GBP
- Report
- January 2023
- 146 Pages
North America
From €3062EUR$3,450USD£2,636GBP
- Report
- December 2021
- 130 Pages
Global
From €13310EUR$14,995USD£11,455GBP
- Report
- July 2022
- 128 Pages
Global
From €1775EUR$2,000USD£1,528GBP
- Report
- October 2024
- 96 Pages
Global
From €3500EUR$4,224USD£3,118GBP
- Report
- June 2023
- 132 Pages
Global
From €843EUR$950USD£726GBP
The Overactive Bladder Drug market is a subset of the Urological Disorders Drugs market. It is composed of drugs used to treat overactive bladder, a condition characterized by frequent urination, urgency, and incontinence. These drugs work by relaxing the bladder muscles, reducing the urge to urinate, and improving bladder control. Commonly used drugs include anticholinergics, beta-3 agonists, and muscarinic receptor antagonists. These drugs are available in both oral and topical formulations.
The Overactive Bladder Drug market is highly competitive, with many companies offering a variety of products. Some of the major players in the market include Pfizer, Astellas Pharma, Allergan, Merck, Sanofi, and GlaxoSmithKline. Show Less Read more
